Table 4. Zinc and selenium levels measured in patients treated with rosuvastatin + mineral supplement or placebo.
| Rosuvastatin + Zn,Se (n = 38) | Rosuvastatin + Placebo (n = 38) | ∆(Zn,Se) – ∆(Placebo) (n = 76) | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Post | P-value | Baseline | Post | P-value | δ (95% CI) 1 | P-value 2 | |
| Plasma zinc (μg/dL) | 84.0 (70.8–101.8) | 90.0 (75.4–101.5) | 0.14 | 77.0 (67.3–95.0) | 82.4 (72.4–98.2) | 0.99 | 1.4 (-7.7–10.5) | 0.77 |
| Erythrocyte zinc (μg/g Hb) | 52. 5 (41.1–62.1) | 50.8 (41.9–57.5) | 0.14 | 49.2 (42.7–57.9) | 50.1 (40.8–59.2) | 0.99 | -1.8 (-7.0–3.3) | 0.19 |
| Plasma selenium (μg/L) | 68.0 (59.9–78.8) | 70.6 (59.8–76.2) | 0.87 | 63.1(52.1–70.0) | 61.9 (56.1–71.6) | 0.63 | -0.1 (-4.6–4.3) | 0.95 |
| Erythrocyte selenium (μg/L) | 104.1 (89.2–139) | 111.8 (99.2–148) | 0.07 | 106 (89.6–129.8) | 114.7 (85–136.6) | 0.99 | -2.0 (-14.9–10.9) | 0.77 |
Data are median (25–75% interquartile range).
1 Difference in response between rosuvastatin + Zn,Se or placebo groups after treatment, with a 95% confidence interval.
2 P-values indicate differences between rosuvastatin + Zn,Se or placebo groups after treatment.
Number of participants with missing data: Plasma zinc and Erythrocyte zinc (02 rosuvastatin+ Zn,Se group; 02 rosuvastatin+placebo group).